Indeed, immunotherapy is the first-line treatment of advanced stage NSCLC patients harboring EGFR/ALK (ALK receptor tyrosine kinase) wild type with PD-L1 expression ≥ 50%, and is the second-line treatment when PD-L1 expression ranges between 1 and 50%. The gene discussed is ALK; the disease is non-small cell lung carcinoma.